Tris Settles Last Pending Suit on Copies of QuilliChew ADHD Drug

Tris Pharma Inc. settled its last pending suit over copies of QuilliChew ER, closing its clash with Ascent Pharmaceuticals Inc. over the chewable extended-release medication for attention deficit hyperactivity disorder.

The agreement comes less than three months after a New Jersey federal judge ruled that Teva Pharmaceutical Industries Ltd.’s generic version infringes five patents, including two of the four at issue against Ascent.

Ascent agreed that its QuilliChew copy is blocked until the latest of the four patents’ expirations, “except as specifically authorized” by the Oct. 27 settlement and license agreement, according to a consent judgment and order ...